Price T Rowe Associates Inc. MD Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Price T Rowe Associates Inc. MD grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,760,444 shares of the medical equipment provider’s stock after buying an additional 176,337 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 0.07% of Zimmer Biomet worth $1,559,147,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $25,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $39,000. OFI Invest Asset Management purchased a new position in Zimmer Biomet during the fourth quarter worth approximately $40,000. SRS Capital Advisors Inc. boosted its stake in Zimmer Biomet by 146.9% during the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 285 shares during the last quarter. Finally, Atala Financial Inc purchased a new stake in Zimmer Biomet in the 4th quarter valued at $51,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 1.4 %

NYSE ZBH opened at $97.51 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm has a market cap of $19.29 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 1.95 and a beta of 0.84. The firm has a 50 day simple moving average of $105.82 and a 200-day simple moving average of $106.62. Zimmer Biomet Holdings, Inc. has a one year low of $93.10 and a one year high of $123.96.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business earned $2.20 earnings per share. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.98%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZBH. Raymond James lowered their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. BTIG Research reiterated a “buy” rating on shares of Zimmer Biomet in a report on Monday, April 14th. JMP Securities reissued a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Royal Bank of Canada lowered their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.